Thiopurine-methyltransferase variants in inflammatory bowel disease: Prevalence and toxicity in Brazilian patients

Table 5 Association between the thiopurine-methyl-transferase polymorphisms and adverse effects in patients with inflammatory bowel disease n (%)

	C238G		G460A/A719G		A719G
Adverse effect	CHz	HTz	CHz	HTz	CHz	HTz
Crohn’s disease	35/143 (24.5)		30/126 (23.8)		33/135 (24.4)
Myelosuppression	0	0	0	0	0	0
Neutropenia	3 (2.1)	0	2 (1.6)	0	2 (1.5)	0
Flu-like symptoms	3 (2.1)	0	3 (2.4)	0	3 (2.2)	0
Nausea/vomiting	12 (8.4)	0	9 (7.1)	1 (0.8)	11 (8.1)	1 (0.7)
Allergy/dermatitis	1 (0.7)	0	2 (1.6)	0	2 (1.5)	0
Hepatotoxicity	5 (3.5)	1 (0.7)	5 (4.0)	0	5 (3.7)	0
Amylase/lipase elevation	6 (4.2)	2 (1.4)	6 (4.7)	0	3 (2.2)	4 (2.9)
Pancreatitis	1 (0.7)	1 (0.7)	2 (1.6)	0	2 (1.5)	0
Ulcerative colitis	14/71 (19.7)		18/68 (26.5)		14/71 (19.7)
Myelosuppression	0	0	0	0	0	0
Neutropenia	0	0	0	0	0	0
Flu-like symptoms)	1 (1.4)	0	1 (1.5)	0	1 (1.4)	0
Nausea/vomiting	4 (5.6)	0	3 (4.4)	0	3 (4.2)	0
Allergy/dermatitis	3 (4.2)	2 (2.8)	3 (4.4)	0	2 (2.8)	0
Hepatotoxicity	0	0	0	0	0	0
Amylase/lipase elevation	2 (2.8)	1 (1.4)	3 (4.4)	0	3 (4.2)	0
Pancreatitis	0	1 (1.4)	1 (1.5)	0	1 (1.4)	0

CHz: Common homozygous; HTz: Heterozygous.